BILL ANALYSIS

HR3491

NEUTRAL

DeOndra Dixon INCLUDE Project Act of 2025

HR3491 (DeOndra Dixon INCLUDE Project Act of 2025) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

2/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

Zero appropriated funds — authorization-only bill has no direct financial impact on companies

Stalled legislative velocity: 1-year gap between introduction and committee markup

No public companies named or financially linked; academic research institutions are the sole beneficiaries if funding materializes

How HR3491 Affects the Market

No publicly traded companies have direct revenue exposure to this authorization-only bill. The research program would benefit academic grantees, not corporate entities. Investors should not adjust positions based on this legislation.

Bill Details

Metric	Value
Bill Number	HR3491
Market Sentiment	neutral
Event Date	May 21, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.

Full AI Market Analysis

The bill, introduced May 2025, authorizes the NIH Director to carry out the INCLUDE Project for Down syndrome research. Its status remains 'Reported out of committee — awaiting floor action' after a unanimous 46-0 committee vote on May 21, 2026. However, the bill explicitly does not appropriate any funds — it merely authorizes a program structure. No dollar amounts appear in the text, and the action history shows nearly a year elapsed between introduction and the single committee markup, indicating low legislative priority. Authorizations without appropriations have no binding effect on federal spending or private sector revenue. The research program, if eventually funded through separate appropriations, would flow through NIH grants to academic institutions and research hospitals, not directly to publicly traded companies. No pharmaceutical, biotech, or diagnostic company is named in the bill or its findings. Related bills (S891, HR1768) cover broader healthcare topics but lack specific Down syndrome funding mechanisms. With no market catalyst, no funding stream, and no named corporate beneficiaries, this bill registers as procedural noise for investors.